Evidence map›Paper›PMID 22448290›Full record

ArticlePloS one2012

Prophylactic application of CpG oligonucleotides augments the early host response and confers protection in acute melioidosis.

Barbara M Judy, Katherine Taylor, Arpaporn Deeraksa, R Katie Johnston, Janice J Endsley, Sudhamathi Vijayakumar, Judith F Aronson, D Mark Estes, Alfredo G Torres

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Single-stranded DNA oligonucleotides containing CpG motifs are non-stimulatoryFrontiers in cellular and infection microbiology · 2024
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Monitoring Therapeutic Treatments againstPathogens (Basel, Switzerland) · 2013
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Barbara M JudyDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Katherine Taylor
Arpaporn Deeraksa
R Katie Johnston
Janice J Endsley
Sudhamathi Vijayakumar
Judith F Aronson
D Mark Estes
Alfredo G Torres
The University of Texas Medical Branch at Galveston · USUniversity of Georgia · US

Funding

WRCE Nonhuman Primate CoreU54AI057156 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI WALKER, DAVID H · 2003 to 2013
$102.6M
Non-invasive Optical Imaging of Select Agent Bacteria in Non-human PrimatesU01AI082103 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI QUINN, FREDERICK D · 2009 to 2010
$2.9M
NIAID NIH HHS 5U01AI082103-02NIAID NIH HHS U01 AI082103NIAID NIH HHS U54 AI057156
6 · The paper itself

Abstract

Prophylactic administration of CpG oligodeoxynucleotides (CpG ODNs) is known to confer protection against lethal sepsis caused by Burkholderia pseudomallei in the mouse model. The mechanisms whereby CpG regulates the innate immune response to provide protection against B. pseudomallei, however, are poorly characterized. In the present study, we demonstrate that intranasal treatment of mice with Class C CpG, results in recruitment of inflammatory monocytes and neutrophils to the lung at 48 h post-treatment. Mice infected with B. pseudomallei 48 h post-CpG treatment had reduced organ bacterial load and significantly altered cytokine and chemokine profiles concomitant with protection as compared to control animals. CpG administration reduced the robust production of chemokines and pro-inflammatory cytokines in blood, lung and spleen, observed following infection of non-treated animals. Death of control animals coincided with the time of peak cytokine production (day 1-3), while a moderate; sustained cytokine production in CpG-treated animals was associated with survival. In general, CpG treatment resulted in diminished expression of cytokines and chemokines post-infection, though IL-12p40 was released in larger quantities in CpG treated animals. In contrast to CpG-treated animals, the lungs of infected control animals were infiltrated with leukocytes, especially neutrophils, and large numbers of necrotic lesions were observed in lung sections. Therapeutic treatment of B. pseudomallei-infected animals with CpG at 24 h post-infection did not impact survival compared to control animals. In summary, protection of CpG-treated animals was associated with recruitment of inflammatory monocytes and neutrophils into the lungs prior to infection. These responses correspond with early control of bacterial growth, a dampened inflammatory cytokine/chemokine response, reduced lung pathology, and greatly increased survival. In contrast, a delay in recruitment of inflammatory cell populations, despite a robust production of pro-inflammatory cytokines, was associated with poorly controlled bacterial growth, severe lung pathology, and death of control animals.

Indexed as

Immunity, InnateAdjuvants, ImmunologicAnimalsBurkholderia pseudomalleiChemokinesCytokinesFemaleFlow CytometryLungMelioidosisMiceMice, Inbred BALB CMonocytesNeutrophilsOligodeoxyribonucleotidesSpleenAdjuvants, ImmunologicChemokinesCPG-oligonucleotideCytokinesOligodeoxyribonucleotides

Identifiers

PMID22448290
PMCPMC3309019
OpenAlexW2031999611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.